Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs

{
  "signal_id": "0fe2f3cc-c7be-1f95-7e65-7b7502774d38",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-28T10:45:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lilly-launches-the-lilly-change-the-course-commitment-aiming-to-address-treatment-gaps-in-diabetes-and-obesity-in-lmics-302890804.html",
    "title": "Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs",
    "excerpt": "Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries, before 2040 Key highlights: INDIANAPOLIS , Sept. 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is launching today the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated with Lilly's innovative diabetes and obesity medicines. This means treating as many people with diabetes and obesity in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries before 2040. Today, for every 4 people in high-income countries who have access to Lilly's diabetes and obesity medicines, only 1 person in low- and middle-income countries can reach them. To close this gap, Lilly will focus on three pillars: starting from clinical development of medicines, their registration and access pathways and health systems strengthening. The announcement follows the completion of the Lilly 30x30 global health initiative five years ahead of schedule, which expanded access to quality healthcare for 40 million people in resource-limited settings in 2025 – exceeding its original goal of reaching 30 million people annually by 2030. Why is Lilly launching a new...",
    "product": "Foundayo",
    "summary": "Eli Lilly and Company launched Foundayo (orforglipron), an FDA-approved oral treatment for adults with obesity or overweight, which was originally discovered by Chugai Pharmaceutical.",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA2971532&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Foundayo",
      "full_text": "Foundayo™ (orforglipron)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-28T10:45:00Z",
    "article_sentence": "Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity.",
    "related_company_name": "Chugai Pharmaceutical Co., Ltd.",
    "related_company_domain": "chugai-pharm.co.jp"
  }
}

curl https://signals.autobound.ai/v1/signals/0fe2f3cc-c7be-1f95-7e65-7b7502774d38 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'